ยินดีต้อนรับคุณ, บุคคลทั่วไป
หน้าหลัก | เข้าสู่ระบบ หรือ ลงทะเบียน
Username: Password:
  วันศุกร์ที่ 29 มีนาคม พ.ศ.2567
  คำค้นหา:
รีวิวเกมจากแฟน GM
รีวิวเกม
สาระน่าเรื่องเกม
บทความเกม
Gamemag online รายสิบวัน
Magazine
Screen Shot
Game Update
คลิปเกมจากยูทูป
Game Tube
Emu และ Rom เกม
Emu&rom
Cosplay
Cosplay
Wallpaper
WallPaper
ภาพวาดจากแฟน GM
Art Corner
Gamemag on Facebook
Facebook
                   
สมาชิกทุกท่านโปรดอ่านก่อน*กฎกติกาของบอร์ด*
รวมวิธีโพสภาพ,คลิป,การใส่ลายเซ็น และอื่นๆ
...
Animategroup.com - GAMEMAG - Novartis announces new organizational structure to accelerate growth
ผู้ตั้งกระทู้ ข้อความ
upamfva / Member
ID : M07665

Level : เกมกดซึเนโอะ
Exp. : 23%
จิตพิสัย : -71%
Like : 0
Post : 619
Reply : 13
Sex : ชาย
วันที่สมัคร : 2021-06-11
PM Profile
Topic : Novartis announces new organizational structure to accelerate growth
«date: 18 เมษายน 2565 , 08:05:38 »
 แก้ไข  

Novartis announces new organizational structure to accelerate growth



Novartis today announced the introduction of a new organizational structure and operating model designed to support the company’s innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.To get more novartis news, you can visit shine news official website.

“The simpler organizational model we are unveiling today is central to our growth strategy as it will make us more agile and competitive, enhance patient and customer orientation, unlock significant potential in our R&D pipeline and drive value-creation through operational efficiencies,” said Vas Narasimhan, CEO Novartis. “With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid- and long-term.”

Integrating Pharmaceuticals and Oncology business units
Novartis will integrate the Pharmaceuticals and Oncology business units and create two separate commercial organizations with a stronger geographic focus—Innovative Medicines US and Innovative Medicines International. The two units will have full P&L responsibility across all therapeutic areas and ownership of customer experience, marketing and sales, and market access for their respective markets. The elevation and establishment of an independent US commercial organization strengthens Novartis’s ability to achieve its goal of becoming a top-five company in the US in terms of sales while maintaining and growing its leadership position internationally. The new model will also help Novartis bring increased focus and commitment to its core therapeutic areas of Cardiovascular, Hematology, Solid Tumors, Immunology and Neuroscience.

Marie-France Tschudin, currently President, Novartis Pharmaceuticals, will become President, Innovative Medicines International and Chief Commercial Officer. In her capacity as Chief Commercial Officer, Marie-France Tschudin will oversee global marketing, medical affairs and value and access across all therapeutic areas. Victor Bulto, currently Head of US Pharmaceuticals, will become President, Innovative Medicines US. They will both report to Vas Narasimhan effective immediately.

New Strategy & Growth Function
Novartis will create a new Strategy & Growth function combining corporate strategy, R&D portfolio strategy and business development. This function will help drive the company’s growth strategy end-to-end and will look across internal and external opportunities to strengthen Novartis’s pipeline with medicines that are both transformational and can make significant contributions to growth. This new function will be led by a Chief Strategy & Growth Officer who will become a member of the ECN and report to the CEO. The search is currently underway for this new leader, and in the interim the function will be led by Lutz Hegemann, M.D., Ph.D., President, Global Health.
Novartis will also combine its Technical Operations and Customer & Technology Solutions units to create a new Operations unit. This new unit will provide a stronger and simpler operational backbone that can accelerate multiple technology transformation initiatives more efficiently, create novel digital solutions at scale and increase productivity, while maintaining industry-leading quality and service levels. Effective immediately, Steffen Lang, currently Global Head of Novartis Technical Operations, will become President, Operations reporting to Vas Narasimhan. In addition, all G&A functions—Finance, People & Organization, Ethics, Risk & Compliance, Legal, and Communications & Engagement—will be integrated on global and country levels.

Novartis has appointed Shreeram Aradhye, M.D., as President, Global Drug Development and Chief Medical Officer effective May 16th, 2022. Dr. Aradhye, who is returning to Novartis, was most recently Executive Vice President and Chief Medical Officer at Dicerna Pharmaceuticals where he led the development of multiple clinical stage RNAi assets. Previously, he was Chief Development Officer at Axcella Health. Dr. Aradhye has dedicated his entire professional career to improving patient lives, first as an academic clinician and then as a drug developer and business leader. He brings significant experience in global clinical development of innovative medicines across several therapeutic areas and has played a key leadership role in the development of multiple innovative therapeutics. During his 20-year tenure at Novartis, he held several global leadership roles including as development head for the company’s Neuroscience franchise and Global Head of Medical Affairs for the Pharmaceuticals business unit. Dr. Aradhye will report to Vas Narasimhan and join the ECN. With the changes in organizational structure and operating model, John Tsai, M.D., has decided to pursue opportunities outside Novartis effective May 15th, 2022.


   ip: 104.233.231.177 
...

ผู้ใช้งานขณะนี้มีผู้ออนไลน์ 10 คน บอรด์มีทั้งหมด : 7,074 กระทู้ รวม  : 30,557 คำตอบ เข้าอ่านกระทู้ทั้งหมด : 14,241,085 ครั้ง
ดูตอบกระทู้ล่าสุดบนบอร์ด

0ขาจร, 10สาวก
ผู้ใช้เมื่อ 5 นาทีที่ผ่านมา:
, , , , , , , , , ,

HBD : no member

 

Copyright 2007 Animate Group Co.,Ltd. All rights reserved.